Skip Navigation


European Heart Journal Advance Access originally published online on January 9, 2005
European Heart Journal
2005 26(3):215-225; doi:10.1093/eurheartj/ehi115
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/3/215    most recent
ehi115v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (232)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Flather, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flather, M. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal vol. 26 no. 3 © The European Society of Cardiology 2005; all rights reserved.

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)

Marcus D. Flather1,2, Marcelo C. Shibata1,3, Andrew J.S. Coats4,*, Dirk J. Van Veldhuisen5, Aleksandr Parkhomenko6, Joszef Borbola7, Alain Cohen-Solal8, Dan Dumitrascu9, Roberto Ferrari10,11, Philippe Lechat12, Jordi Soler-Soler13, Luigi Tavazzi14, Lenka Spinarova15, Jiri Toman15,{dagger}, Michael Böhm16, Stefan D. Anker17, Simon G. Thompson18 and Philip A. Poole-Wilson2 on behalf of the SENIORS Investigators{ddagger}

1Clinical Trials and Evaluation Unit, Royal Brompton and Harefield NHS Trust, London, UK
2National Heart and Lung Institute, Imperial College of Science Technology and Medicine, London, UK
3Division of Cardiology, University of Alberta, Edmonton, Canada
4Faculty of Medicine, University of Sydney, Sydney 2006, Australia
5Department of Cardiology, University Hospital, Groningen, The Netherlands
6Institute of Cardiology, Academy of Science of Ukraine, Kiev, Ukraine
7Hungarian Institute of Cardiology, Budapest, Hungary
8Service de Cardiologie, Hôpital Beaujon, Clichy, France
9University of Pharmacy and Medicine, Cluj Napoca, Romania
10Department of Cardiology, University of Ferrara, Ferrara, Italy
11Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS, Gussago, Italy
12Service de Pharmacologie, Hôpital Pitie-Salpetrière, Paris, France
13Cardiology Division, Hospital General Vall d'Hebron, Barcelona, Spain
14Department of Cardiology, IRCCS Policlinico San Matteo, Pavia, Italy
151st Department of Medicine, Masaryk University Hospital, Brno, Czech Republic
16Universitätskliniken des Saarlandes, Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Homburg/Saar, Germany
17Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany
18Medical Research Council Biostatistics Unit, Cambridge, UK

Received 26 November 2004; revised 10 December 2004; accepted 15 December 2004; online publish-ahead-of-print 9 January 2005.

* Corresponding author. Tel: +61293514579; fax +61293516645. E-mail address: ajscoats{at}aol.com

See page 203 for the editorial comment on this article (doi:10.1093/eurheartj/ehi118)

Aims Large randomized trials have shown that beta-blockers reduce mortality and hospital admissions in patients with heart failure. The effects of beta-blockers in elderly patients with a broad range of left ventricular ejection fraction are uncertain. The SENIORS study was performed to assess effects of the beta-blocker, nebivolol, in patients ≥70 years, regardless of ejection fraction.

Methods and results We randomly assigned 2128 patients aged ≥70 years with a history of heart failure (hospital admission for heart failure within the previous year or known ejection fraction ≤35%), 1067 to nebivolol (titrated from 1.25 mg once daily to 10 mg once daily), and 1061 to placebo. The primary outcome was a composite of all cause mortality or cardiovascular hospital admission (time to first event). Analysis was by intention to treat. Mean duration of follow-up was 21 months. Mean age was 76 years (SD 4.7), 37% were female, mean ejection fraction was 36% (with 35% having ejection fraction >35%), and 68% had a prior history of coronary heart disease. The mean maintenance dose of nebivolol was 7.7 mg and of placebo 8.5 mg. The primary outcome occurred in 332 patients (31.1%) on nebivolol compared with 375 (35.3%) on placebo [hazard ratio (HR) 0.86, 95% CI 0.74–0.99; P=0.039]. There was no significant influence of age, gender, or ejection fraction on the effect of nebivolol on the primary outcome. Death (all causes) occurred in 169 (15.8%) on nebivolol and 192 (18.1%) on placebo (HR 0.88, 95% CI 0.71–1.08; P=0.21).

Conclusion Nebivolol, a beta-blocker with vasodilating properties, is an effective and well-tolerated treatment for heart failure in the elderly.

Key Words: Heart failure • Elderly • Beta-blocker • Nebivolol • Randomized trial • Ejection fraction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Making sense of SENIORS
John McMurray
EHJ 2005 26: 203-206. [Extract] [FREE Full Text]  



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
M. Lainscak, H.-D. Duengen, and S. D. Anker
Beta-Blockers in Elderly Patients With Heart Failure: Ready for Prime Time?
J. Am. Coll. Cardiol., December 1, 2009; 54(23): 2202 - 2202.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. Triposkiadis, G. Karayannis, G. Giamouzis, J. Skoularigis, G. Louridas, and J. Butler
The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
J. Am. Coll. Cardiol., November 3, 2009; 54(19): 1747 - 1762.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Munzel and T. Gori
Nebivolol The Somewhat-Different beta-Adrenergic Receptor Blocker.
J. Am. Coll. Cardiol., October 13, 2009; 54(16): 1491 - 1499.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
G. Jondeau, Y. Neuder, J.-C. Eicher, P. Jourdain, E. Fauveau, M. Galinier, A. Jegou, F. Bauer, J. N. Trochu, A. Bouzamondo, et al.
B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode
Eur. Heart J., September 2, 2009; 30(18): 2186 - 2192.
[Abstract] [Full Text] [PDF]


Home page
Cleveland Clinic Journal of MedicineHome page
Q. CHE, M. J. SCHREIBER JR, and M. A. RAFEY
Beta-blockers for hypertension: Are they going out of style?
Cleveland Clinic Journal of Medicine, September 1, 2009; 76(9): 533 - 542.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
A. Cohen-Solal, D. Kotecha, D. J van Veldhuisen, D. Babalis, M. Bohm, A. J. Coats, M. Roughton, P. Poole-Wilson, L. Tavazzi, M. Flather, et al.
Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial
Eur J Heart Fail, September 1, 2009; 11(9): 872 - 880.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
A. Maffei and G. Lembo
Nitric oxide mechanisms of nebivolol
Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 317 - 327.
[Abstract] [PDF]


Home page
Eur J Heart FailHome page
J. G.F. Cleland, A. P. Coletta, A. Torabi, and A. L. Clark
Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF
Eur J Heart Fail, August 1, 2009; 11(8): 802 - 805.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. J. van Veldhuisen, A. Cohen-Solal, M. Bohm, S. D. Anker, D. Babalis, M. Roughton, A. J.S. Coats, P. A. Poole-Wilson, M. D. Flather, and SENIORS Investigators
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
J. Am. Coll. Cardiol., June 9, 2009; 53(23): 2150 - 2158.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. W. Armstrong and K. P. Alexander
Nebivolol in older adults with heart failure reduced rates for seniors?
J. Am. Coll. Cardiol., June 9, 2009; 53(23): 2159 - 2161.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
F. A. McAlister, N. Wiebe, J. A. Ezekowitz, A. A. Leung, and P. W. Armstrong
Meta-analysis: {beta}-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure
Ann Intern Med, June 2, 2009; 150(11): 784 - 794.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
H. Krum
Consider {beta} blockers for patients with heart failure
BMJ, June 1, 2009; 338(jun01_2): b1728 - b1728.
[Full Text]


Home page
JAMAHome page
H.-P. B. La Rocca, P. Buser, and M. Pfisterer
BNP-Guided Heart Failure Therapy in Older Patients--Reply
JAMA, May 27, 2009; 301(20): 2092 - 2093.
[Full Text] [PDF]


Home page
Eur Heart JHome page
S. M. Shaw and S. G. Williams
Should beta-blockade continue to be withheld from patients with chronic heart failure and asthma?
Eur. Heart J., May 2, 2009; 30(10): 1287 - 1287.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. Rozec, M. Erfanian, K. Laurent, J.-N. Trochu, and C. Gauthier
Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1532 - 1538.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J.-L. Balligand
beta(3)-Adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade "Stop or Encore?".
J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1539 - 1542.
[Full Text] [PDF]


Home page
Fam PractHome page
M. J Calvert, A. Shankar, R. J McManus, R. Ryan, and N. Freemantle
Evaluation of the management of heart failure in primary care
Fam. Pract., April 1, 2009; 26(2): 145 - 153.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart Fail SupplHome page
M. Komajda
Heart failure guidelines in North America and Europe: agreement or disagreement?
Eur J Heart Fail Suppl, April 1, 2009; 8(suppl_1): i11 - i14.
[Full Text] [PDF]


Home page
Eur J Heart Fail SupplHome page
H.J. Dargie
Current controversies in drug use
Eur J Heart Fail Suppl, April 1, 2009; 8(suppl_1): i15 - i20.
[Full Text] [PDF]


Home page
CMAJHome page
K. Tzanetos, D. Leong, and R. C. Wu
Office management of patients with diastolic heart failure
Can. Med. Assoc. J., March 3, 2009; 180(5): 520 - 527.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
E. Erdmann
Safety and tolerability of beta-blockers: prejudices and reality
Eur. Heart J. Suppl., March 1, 2009; 11(suppl_A): A21 - A25.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
R. Willenheimer
The current role of beta-blockers in chronic heart failure: with special emphasis on the CIBIS III trial
Eur. Heart J. Suppl., March 1, 2009; 11(suppl_A): A15 - A20.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. J. Benjamin, P.-S. Chen, D. E. Bild, A. M. Mascette, C. M. Albert, A. Alonso, H. Calkins, S. J. Connolly, A. B. Curtis, D. Darbar, et al.
Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop
Circulation, February 3, 2009; 119(4): 606 - 618.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. Metra, L. Dei Cas, and B. M. Massie
Treatment of heart failure in the elderly: never say it's too late
Eur. Heart J., February 2, 2009; 30(4): 391 - 393.
[Full Text] [PDF]


Home page
JAMAHome page
M. Pfisterer, P. Buser, H. Rickli, M. Gutmann, P. Erne, P. Rickenbacher, A. Vuillomenet, U. Jeker, P. Dubach, H. Beer, et al.
BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial
JAMA, January 28, 2009; 301(4): 383 - 392.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. F. Hernandez, B. G. Hammill, C. M. O'Connor, K. A. Schulman, L. H. Curtis, and G. C. Fonarow
Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry.
J. Am. Coll. Cardiol., January 13, 2009; 53(2): 184 - 192.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
F. Orso, S. Baldasseroni, G. Fabbri, L. Gonzini, D. Lucci, C. D'Ambrosi, M. Gobbi, G. Lecchi, S. Randazzo, G. Masotti, et al.
Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure
Eur J Heart Fail, January 1, 2009; 11(1): 77 - 84.
[Abstract] [Full Text] [PDF]


Home page
ESC Textbook of Cardiovascular MedicineHome page
J. McMurray, M. Petrie, K. Swedberg, M. Komajda, S. Anker, and R. Gardner
CHAPTER 23 Heart Failure
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
A. S. Go, J. Yang, J. H. Gurwitz, J. Hsu, K. Lane, and R. Platt
Comparative Effectiveness of Different {beta}-Adrenergic Antagonists on Mortality Among Adults With Heart Failure in Clinical Practice
Arch Intern Med, December 8, 2008; 168(22): 2415 - 2421.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, et al.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
Eur. Heart J., October 1, 2008; 29(19): 2388 - 2442.
[Full Text] [PDF]


Home page
Eur J Heart FailHome page
K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, et al.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
Eur J Heart Fail, October 1, 2008; 10(10): 933 - 989.
[Full Text] [PDF]


Home page
Circ Heart FailHome page
D. M. Henkel, M. M. Redfield, S. A. Weston, Y. Gerber, and V. L. Roger
Death in Heart Failure: A Community Perspective
Circ Heart Fail, July 1, 2008; 1(2): 91 - 97.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
C. L. Gray and U. A. Ndefo
Nebivolol: A new antihypertensive agent
Am. J. Health Syst. Pharm., June 15, 2008; 65(12): 1125 - 1133.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
M. Nishio, Y. Sakata, T. Mano, T. Ohtani, Y. Takeda, T. Miwa, M. Hori, T. Masuyama, T. Kondo, and K. Yamamoto
Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats
Eur J Heart Fail, May 1, 2008; 10(5): 446 - 453.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
W. J. Remme
Filling the gap between guidelines and clinical practice in heart failure treatment -- Still a far cry from reality
Eur J Heart Fail, December 1, 2007; 9(12): 1143 - 1145.
[Full Text] [PDF]


Home page
Eur J Heart FailHome page
W. J. Remme, J. G. Cleland, L. Erhardt, P. Spark, C. Torp-Pedersen, M. Metra, M. Komajda, C. Moullet, M. A. Lukas, P. Poole-Wilson, et al.
Effect of carvedilol and metoprolol on the mode of death in patients with heart failure
Eur J Heart Fail, November 1, 2007; 9(11): 1128 - 1135.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Maffei, A. Di Pardo, R. Carangi, P. Carullo, R. Poulet, M. T. Gentile, C. Vecchione, and G. Lembo
Nebivolol Induces Nitric Oxide Release in the Heart Through Inducible Nitric Oxide Synthase Activation
Hypertension, October 1, 2007; 50(4): 652 - 656.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J. Patel and J. T. Heywood
Mode of Death in Patients With Systolic Heart Failure
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 127 - 136.
[Abstract] [PDF]


Home page
Eur Heart JHome page
M. Komajda, O. Hanon, M. Hochadel, F. Follath, K. Swedberg, A. Gitt, and J. G.F. Cleland
Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I
Eur. Heart J., June 1, 2007; 28(11): 1310 - 1318.
[Abstract] [Full Text] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
A. Ahmed
Digoxin and Reduction in Mortality and Hospitalization in Geriatric Heart Failure: Importance of Low Doses and Low Serum Concentrations
J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2007; 62(3): 323 - 329.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
D. Dobre, D. J. van Veldhuisen, M. J.L. DeJongste, C. Lucas, G. Cleuren, R. Sanderman, A. V. Ranchor, and F. M. Haaijer-Ruskamp
Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival
Eur J Heart Fail, March 1, 2007; 9(3): 280 - 286.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
I. A. Nasr, A. Bouzamondo, J.-S. Hulot, O. Dubourg, J.-Y. Le Heuzey, and P. Lechat
Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis
Eur. Heart J., February 8, 2007; (2007) ehl484v1.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L. W. Eurlings, J. L. Januzzi, and Y. M. Pinto
Is acute heart failure a highly prevalent orphan disease?
Eur. Heart J., November 2, 2006; 27(22): 2619 - 2620.
[Full Text] [PDF]


Home page
Eur Heart JHome page
J. G.F. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, J. Taylor, and on behalf of PEP-CHF Investigators
The perindopril in elderly people with chronic heart failure (PEP-CHF) study
Eur. Heart J., October 1, 2006; 27(19): 2338 - 2345.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
C. Opasich, A. Boccanelli, M. Cafiero, V. Cirrincione, D. Del Sindaco, A. D. Lenarda, S. D. Luzio, P. Faggiano, M. Frigerio, D. Lucci, et al.
Programme to improve the use of beta-blockers for heart failure in the elderly and in those with severe symptoms: Results of the BRING-UP 2 Study
Eur J Heart Fail, October 1, 2006; 8(6): 649 - 657.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
P. A Poole-Wilson, A. R. Lyon, and A. M. Jacques
A commentary on clinical trials in chronic heart failure.
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 242 - 245.
[Abstract] [PDF]


Home page
Anesth. Analg.Home page
L. Groban and J. Butterworth
Perioperative management of chronic heart failure.
Anesth. Analg., September 1, 2006; 103(3): 557 - 575.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Aguiar-Souto, P. Garcia-Pavia, L. Silva-Melchor, and F. J. Ortigosa
Diagnosis and Management of Chronic Heart Failure
J. Am. Coll. Cardiol., July 4, 2006; 48(1): 223 - 223.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
A. Veverka, D. S Nuzum, and J. L Jolly
Nebivolol: A Third-Generation {beta}-Adrenergic Blocker
Ann. Pharmacother., July 1, 2006; 40(7): 1353 - 1360.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
P. Lechat
The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS
Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C5 - C12.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
C. Funck-Brentano
Beta-blockade in CHF: from contraindication to indication
Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C19 - C27.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
F. Follath
Beta-blockade today: the gap between evidence and practice
Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C28 - C34.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. R. Meyer, E. Haas, and M. Barton
Gender Differences of Cardiovascular Disease: New Perspectives for Estrogen Receptor Signaling
Hypertension, June 1, 2006; 47(6): 1019 - 1026.
[Full Text] [PDF]


Home page
Eur J Heart FailHome page
H. Krum, J. Hill, F. Fruhwald, C. Sharpe, G. Abraham, J.-R. Zhu, C. Poy, and J.A. Kragten
Tolerability of beta-blockers in elderly patients with chronic heart failure: The COLA II study
Eur J Heart Fail, May 1, 2006; 8(3): 302 - 307.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. D. Flather, P. A. Poole-Wilson, A. J.S. Coats, and On behalf of the SENIORS Steering Committee
Beta-blockers and heart failure in older people: reply
Eur. Heart J., April 1, 2006; 27(7): 888 - 888.
[Full Text] [PDF]


Home page
HeartHome page
A J B Brady and P A Poole-Wilson
ESC-CHF: guidelines for the aspirational and the practical.
Heart, April 1, 2006; 92(4): 437 - 440.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D. G. Le Couteur, L. Bailey, and V. Naganathan
Beta-blockers and heart failure in older people
Eur. Heart J., April 1, 2006; 27(7): 887 - 888.
[Full Text] [PDF]


Home page
Eur Heart JHome page
J. J.V. McMurray
Beta-blockers and heart failure in older people: reply
Eur. Heart J., April 1, 2006; 27(7): 888 - 889.
[Full Text] [PDF]


Home page
Eur Heart JHome page
M. L. Lindsey and G. L. Freeman
{beta}-Blockade in heart failure: adding SENIORS to the mix
Eur. Heart J., March 1, 2006; 27(5): 506 - 507.
[Full Text] [PDF]


Home page
Eur Heart JHome page
S. Ghio, G. Magrini, A. Serio, C. Klersy, A. Fucilli, A. Ronaszeki, P. Karpati, G. Mordenti, A. Capriati, P. A. Poole-Wilson, et al.
Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy
Eur. Heart J., March 1, 2006; 27(5): 562 - 568.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
R. E. Gilbert, K. Connelly, D. J. Kelly, C. A. Pollock, and H. Krum
Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 193 - 208.
[Abstract] [Full Text] [PDF]


Home page
Br Med BullHome page
N. D Gillespie
The diagnosis and management of chronic heart failure in the older patient
Br. Med. Bull., February 22, 2006; 75-76(1): 49 - 62.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2125 - 2133.
[Full Text] [PDF]


Home page
Eur Heart JHome page
M. J. Lenzen, E. Boersma, W. J.M. Scholte op Reimer, A. H.M.M. Balk, M. Komajda, K. Swedberg, F. Follath, M. Jimenez-Navarro, M. L. Simoons, and J. G.F. Cleland
Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure
Eur. Heart J., December 2, 2005; 26(24): 2706 - 2713.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
M. C. Shibata, C. M. Soneff, and R. T. Tsuyuki
Utilization of evidence-based therapies for heart failure in the institutionalized elderly
Eur J Heart Fail, December 1, 2005; 7(7): 1122 - 1125.
[Abstract] [Full Text] [PDF]


Home page
Evid. Based Med.Home page
Other articles noted
Evid. Based Med., October 1, 2005; 10(5): 157 - 158.
[Full Text] [PDF]


Home page
CirculationHome page
C. Dessy, J. Saliez, P. Ghisdal, G. Daneau, I. I. Lobysheva, F. Frerart, C. Belge, K. Jnaoui, P. Noirhomme, O. Feron, et al.
Endothelial {beta}3-Adrenoreceptors Mediate Nitric Oxide-Dependent Vasorelaxation of Coronary Microvessels in Response to the Third-Generation {beta}-Blocker Nebivolol
Circulation, August 23, 2005; 112(8): 1198 - 1205.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
J. McMurray, A. Cohen-Solal, R. Dietz, E. Eichhorn, L. Erhardt, F.D. R. Hobbs, H. Krum, A. Maggioni, R. S. McKelvie, I. L. Pina, et al.
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice
Eur J Heart Fail, August 1, 2005; 7(5): 710 - 721.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, K. Swedberg, Writing Committee:, J. Cleland, H. Dargie, H. Drexler, F. Follath, M. Komajda, L. Tavazzi, O. A. Smiseth, et al.
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
Eur. Heart J., June 1, 2005; 26(11): 1115 - 1140.
[Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
K. Swedberg
Review: Effective Implementation of the New ESC Guidelines for the Management of Chronic Heart Failure in Routine Clinical Practice
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2_suppl): S6 - S10.
[Abstract] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
P. C. Burger and H. B.-L. Rocca
Pharmacotherapy of Congestive Heart Failure in Elderly Patients
Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2005; 10(2): 85 - 94.
[Abstract] [PDF]


Home page
Eur Heart JHome page
J. McMurray
Making sense of SENIORS
Eur. Heart J., February 1, 2005; 26(3): 203 - 206.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.